Literature DB >> 16820900

Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival.

Giuseppe Giuffrè1, Francesco Arena, Rosa Scarfì, Angela Simone, Paolo Todaro, Giovanni Tuccari.   

Abstract

We have investigated Lf immunoexpression as well as its biological meaning in 71 formalin-fixed, paraffin-embedded surgical samples of endometrial carcinomas (EC); 64 EC were endometrioid type, whereas 7 were non-endometrioid carcinomas. Immunohistochemistry was performed by primary antibodies against Lactoferrin (Lf), estrogen receptor (ER), progesterone receptor (PR) and Ki-67 antigen. Quantification of Lf immunoreactivity was performed using an intensity-distribution (ID) score. Moreover, the AgNOR technique according to guidelines of the Committee on AgNOR Quantification was used to assess the proliferation rate (NORA). A variable expression of Lf was revealed in 43 cases (61%) of EC. Endometrioid type carcinoma showed a significant higher Lf ID-score than non-endometrioid type; in contrast, no relationships were demonstrated between Lf immunoexpression and histologic grade, stage, clinical course as well as proliferative activity of EC. Moreover, a significantly higher Lf ID-score was encountered in ER-positive carcinomas. Survival analysis in EC indicated the architectural, nuclear and combined histologic grades as well as the stage, PR, Ki-67 and NORA as significant parameters. The utilization of Lf as a prognostic marker, able to identify patients at different risk of death, or alternatively, its clinical application as therapeutic agent, must be considered with great caution.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820900

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Does lactoferrin behave as an immunohistochemical oncofetal marker in bone and cartilage human neoplasms?

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Giuseppe Speciale; Michele A Rosa; Giovanni Tuccari
Journal:  Pathol Oncol Res       Date:  2010-10-24       Impact factor: 3.201

2.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

3.  Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup.

Authors:  Antonio Ieni; Valeria Barresi; Luana Licata; Roberta Cardia; Carmine Fazzari; Giuseppe Nuciforo; Francesco Caruso; Michele Caruso; Vincenzo Adamo; Giovanni Tuccari
Journal:  Oncol Lett       Date:  2017-03-14       Impact factor: 2.967

4.  Lactoferrin immuno-expression in human normal and neoplastic bone tissue.

Authors:  Antonio Ieni; Valeria Barresi; Maddalena Grosso; Michele Attilio Rosa; Giovanni Tuccari
Journal:  J Bone Miner Metab       Date:  2009-02-26       Impact factor: 2.626

5.  Growth differentiation factor-15 and lactoferrin immuno-expression in breast cancer: relationship with body iron-status and survival outcome.

Authors:  Zheng Zhang; Hao-Jie Jiang; Huan-Huan Yang; Jin-Jin Ren; Guo-Qin Jiang; Jia-Ying Xu; Li-Qiang Qin
Journal:  Biometals       Date:  2021-01-23       Impact factor: 2.949

6.  Immunoexpression of lactoferrin in bone metastases and corresponding primary carcinomas.

Authors:  A Ieni; V Barresi; G Branca; G Giuffrè; M A Rosa; G Tuccari
Journal:  Oncol Lett       Date:  2013-03-05       Impact factor: 2.967

7.  Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps: A comparison between benign and malignant polyps in postmenopausal patients.

Authors:  Armando Antunes; José Vassallo; Anderson Pinheiro; Rogério Leão; Aarão Mendes Pinto Neto; Lucia Costa-Paiva
Journal:  Oncol Lett       Date:  2014-03-28       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.